SMN2 and proximal spinal muscular atrophy: Treatment of patients with the antisense oligonucleotide Spinraza, which skews splicing of SMN2 towards full length transcripts, improves survival and motor milestone achievement in children with infantile onset SMA (ie, type 1) and motor function in SMA type 2.4